LXEO Lexeo Therapeutics | $8.20
+2.1% | 10/7/2025 | | Boost Price Target | $9.00 ➝ $20.00 | Outperform | 00.00% | View details for Leerink Partners rating of Lexeo Therapeutics (NASDAQ:LXEO) on 10/7/2025 |
MRUS Merus | $94.58
+0.2% | 10/6/2025 | | Reiterated Rating | $95.00 ➝ $97.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Merus (NASDAQ:MRUS) on 10/6/2025 |
CAH Cardinal Health | $157.24
-0.3% | 10/6/2025 | | Boost Price Target | $186.00 ➝ $187.00 | Outperform | 00.00% | View details for Leerink Partners rating of Cardinal Health (NYSE:CAH) on 10/6/2025 |
LBRX LB Pharmaceuticals | $15.64
+4.0% | 10/6/2025 | | Initiated Coverage | $34.00 | Outperform | 00.00% | View details for Leerink Partners rating of LB Pharmaceuticals (NASDAQ:LBRX) on 10/6/2025 |
IMAB I-Mab | $4.85
-4.3% | 10/3/2025 | | Initiated Coverage | $9.00 | Outperform | 00.00% | View details for Leerink Partners rating of I-Mab (NASDAQ:IMAB) on 10/3/2025 |
RCKT Rocket Pharmaceuticals | $3.67
+8.3% | 10/3/2025 | | Lower Price Target | $9.00 ➝ $7.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 10/3/2025 |
BSX Boston Scientific | $97.28
+0.5% | 10/1/2025 | | Boost Price Target | $127.00 ➝ $128.00 | Outperform | 00.00% | View details for Leerink Partners rating of Boston Scientific (NYSE:BSX) on 10/1/2025 |
CRNX Crinetics Pharmaceuticals | $45.76
+3.0% | 9/29/2025 | | Boost Price Target | $80.00 ➝ $88.00 | Outperform | 00.00% | View details for Leerink Partners rating of Crinetics Pharmaceuticals (NASDAQ:CRNX) on 9/29/2025 |
RAPT Rapt Therapeutics | $30.01
+1.9% | 9/26/2025 | | Upgrade | $16.00 ➝ $37.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Rapt Therapeutics (NASDAQ:RAPT) on 9/26/2025 |
CTNM Contineum Therapeutics | $12.16
| 9/25/2025 | | Initiated Coverage | $20.00 | Outperform | 00.00% | View details for Leerink Partners rating of Contineum Therapeutics (NASDAQ:CTNM) on 9/25/2025 |
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. |
GH Guardant Health | $65.26
-0.1% | 9/25/2025 | | Boost Price Target | $70.00 ➝ $75.00 | Outperform | 00.00% | View details for Leerink Partners rating of Guardant Health (NASDAQ:GH) on 9/25/2025 |
VRTX Vertex Pharmaceuticals | $414.86
-1.5% | 9/25/2025 | | Upgrade | $458.00 ➝ $456.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Vertex Pharmaceuticals (NASDAQ:VRTX) on 9/25/2025 |
MCK McKesson | $758.07
+0.3% | 9/24/2025 | | Boost Price Target | $785.00 ➝ $850.00 | Outperform | 00.00% | View details for Leerink Partners rating of McKesson (NYSE:MCK) on 9/24/2025 |
MTSR Metsera | $52.60
-0.5% | 9/24/2025 | | Reiterated Rating | $77.00 ➝ $57.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Metsera (NASDAQ:MTSR) on 9/24/2025 |
QURE uniQure | $63.65
+6.1% | 9/24/2025 | | Boost Price Target | $48.00 ➝ $68.00 | Outperform | 00.00% | View details for Leerink Partners rating of uniQure (NASDAQ:QURE) on 9/24/2025 |
NBTX Nanobiotix | $29.91
+9.6% | 9/18/2025 | | Set Price Target | $14.00 | | 00.00% | View details for Leerink Partners rating of Nanobiotix (NASDAQ:NBTX) on 9/18/2025 |
IPHA Innate Pharma | $2.04
+1.2% | 9/18/2025 | | Reiterated Rating | $10.00 ➝ $2.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Innate Pharma (NASDAQ:IPHA) on 9/18/2025 |
ROIV Roivant Sciences | $16.12
+0.6% | 9/18/2025 | | Boost Price Target | $18.00 ➝ $22.00 | Outperform | 00.00% | View details for Leerink Partners rating of Roivant Sciences (NASDAQ:ROIV) on 9/18/2025 |
SABS SAB Biotherapeutics | $2.50
+6.8% | 9/17/2025 | | Initiated Coverage | $7.00 | Outperform | 00.00% | View details for Leerink Partners rating of SAB Biotherapeutics (NASDAQ:SABS) on 9/17/2025 |
ATYR aTyr Pharma | $0.95
-4.7% | 9/15/2025 | | Reiterated Rating | | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of aTyr Pharma (NASDAQ:ATYR) on 9/15/2025 |
SRRK Scholar Rock | $40.99
+5.9% | 9/15/2025 | | Initiated Coverage | $51.00 | Outperform | 00.00% | View details for Leerink Partners rating of Scholar Rock (NASDAQ:SRRK) on 9/15/2025 |
PTGX Protagonist Therapeutics | $67.04
+2.7% | 9/12/2025 | | Initiated Coverage | $73.00 | Outperform | 00.00% | View details for Leerink Partners rating of Protagonist Therapeutics (NASDAQ:PTGX) on 9/12/2025 |
MTSR Metsera | $52.60
-0.5% | 9/9/2025 | | Initiated Coverage | $77.00 | Outperform | 00.00% | View details for Leerink Partners rating of Metsera (NASDAQ:MTSR) on 9/9/2025 |
SRPT Sarepta Therapeutics | $23.13
-1.1% | 9/9/2025 | | Boost Price Target | $12.00 ➝ $15.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Sarepta Therapeutics (NASDAQ:SRPT) on 9/9/2025 |
MD Pediatrix Medical Group | $16.22
-5.3% | 9/5/2025 | | Boost Price Target | $14.50 ➝ $17.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Pediatrix Medical Group (NYSE:MD) on 9/5/2025 |
WVE WAVE Life Sciences | $8.19
+11.4% | 9/3/2025 | | Set Price Target | $26.00 | | 00.00% | View details for Leerink Partners rating of WAVE Life Sciences (NASDAQ:WVE) on 9/3/2025 |
ARCT Arcturus Therapeutics | $19.68
-7.2% | 8/22/2025 | | Lower Price Target | $63.00 ➝ $54.00 | Outperform | 00.00% | View details for Leerink Partners rating of Arcturus Therapeutics (NASDAQ:ARCT) on 8/22/2025 |
MRNA Moderna | $27.53
-1.4% | 8/22/2025 | | Lower Price Target | $18.00 ➝ $15.00 | Underperform | 00.00% | View details for Leerink Partners rating of Moderna (NASDAQ:MRNA) on 8/22/2025 |
PINC Premier | $27.89
-1.1% | 8/19/2025 | | Boost Price Target | $24.00 ➝ $26.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Premier (NASDAQ:PINC) on 8/19/2025 |
XERS Xeris Biopharma | $8.19
-0.1% | 8/19/2025 | | Boost Price Target | $7.00 ➝ $9.00 | Outperform | 00.00% | View details for Leerink Partners rating of Xeris Biopharma (NASDAQ:XERS) on 8/19/2025 |
INSP Inspire Medical Systems | $80.21
+2.1% | 8/15/2025 | | Lower Price Target | $116.00 ➝ $97.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Inspire Medical Systems (NYSE:INSP) on 8/15/2025 |
MGNX MacroGenics | $1.75
-1.7% | 8/15/2025 | | Lower Price Target | $8.00 ➝ $5.00 | Outperform | 00.00% | View details for Leerink Partners rating of MacroGenics (NASDAQ:MGNX) on 8/15/2025 |
STTK Shattuck Labs | $2.20
-7.9% | 8/14/2025 | | Lower Price Target | $4.00 ➝ $2.00 | Outperform | 00.00% | View details for Leerink Partners rating of Shattuck Labs (NASDAQ:STTK) on 8/14/2025 |
BHVN Biohaven | $17.23
+12.3% | 8/12/2025 | | Lower Price Target | $60.00 ➝ $50.00 | Outperform | 00.00% | View details for Leerink Partners rating of Biohaven (NYSE:BHVN) on 8/12/2025 |
CAH Cardinal Health | $157.24
-0.3% | 8/12/2025 | | Lower Price Target | $188.00 ➝ $186.00 | Outperform | 00.00% | View details for Leerink Partners rating of Cardinal Health (NYSE:CAH) on 8/12/2025 |
LLY Eli Lilly and Company | $854.40
+1.0% | 8/7/2025 | | Reiterated Rating | $715.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Eli Lilly and Company (NYSE:LLY) on 8/7/2025 |
ADAG Adagene | $1.95
-0.3% | 8/6/2025 | | Initiated Coverage | $7.00 | Outperform | 00.00% | View details for Leerink Partners rating of Adagene (NASDAQ:ADAG) on 8/6/2025 |
CYRX CryoPort | $9.94
-1.2% | 8/6/2025 | | Upgrade | $16.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of CryoPort (NASDAQ:CYRX) on 8/6/2025 |
XLO Xilio Therapeutics | $0.84
-0.3% | 8/6/2025 | | Initiated Coverage | $2.00 | Outperform | 00.00% | View details for Leerink Partners rating of Xilio Therapeutics (NASDAQ:XLO) on 8/6/2025 |
MASS 908 Devices | $8.80
-3.8% | 8/5/2025 | | Upgrade | $12.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of 908 Devices (NASDAQ:MASS) on 8/5/2025 |
|
CELC Celcuity | $49.47
-0.1% | 7/28/2025 | | Boost Price Target | $28.00 ➝ $60.00 | Outperform | 00.00% | View details for Leerink Partners rating of Celcuity (NASDAQ:CELC) on 7/28/2025 |
ABVX Abivax | $90.61
+4.7% | 7/23/2025 | | Set Price Target | $74.00 | Outperform | 00.00% | View details for Leerink Partners rating of Abivax (NASDAQ:ABVX) on 7/23/2025 |
REPL Replimune Group | $4.63
+1.3% | 7/22/2025 | | Reiterated Rating | $21.00 ➝ $3.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Replimune Group (NASDAQ:REPL) on 7/22/2025 |
SRPT Sarepta Therapeutics | $23.13
-1.1% | 7/21/2025 | | Reiterated Rating | | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Sarepta Therapeutics (NASDAQ:SRPT) on 7/21/2025 |
ELV Elevance Health | $358.24
-1.1% | 7/18/2025 | | Reiterated Rating | $510.00 ➝ $310.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Elevance Health (NYSE:ELV) on 7/18/2025 |
ELAN Elanco Animal Health | $20.06
-1.4% | 7/17/2025 | | Upgrade | $18.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Elanco Animal Health (NYSE:ELAN) on 7/17/2025 |
IDXX IDEXX Laboratories | $628.75
-0.2% | 7/17/2025 | | Boost Price Target | $580.00 ➝ $600.00 | Outperform | 00.00% | View details for Leerink Partners rating of IDEXX Laboratories (NASDAQ:IDXX) on 7/17/2025 |
ZTS Zoetis | $143.32
-0.1% | 7/17/2025 | | Downgrade | $180.00 ➝ $155.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Zoetis (NYSE:ZTS) on 7/17/2025 |
HSIC Henry Schein | $64.57
-0.2% | 7/14/2025 | | Set Price Target | $75.00 | | 00.00% | View details for Leerink Partners rating of Henry Schein (NASDAQ:HSIC) on 7/14/2025 |
PGNY Progyny | $20.57
0.0% | 7/8/2025 | | Upgrade | $28.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Progyny (NASDAQ:PGNY) on 7/8/2025 |
ABCL AbCellera Biologics | $5.91
-4.2% | 7/7/2025 | | Initiated Coverage | $5.00 | Outperform | 00.00% | View details for Leerink Partners rating of AbCellera Biologics (NASDAQ:ABCL) on 7/7/2025 |
COGT Cogent Biosciences | $16.19
+3.9% | 7/7/2025 | | Boost Price Target | $16.00 ➝ $18.00 | Outperform | 00.00% | View details for Leerink Partners rating of Cogent Biosciences (NASDAQ:COGT) on 7/7/2025 |
KALV KalVista Pharmaceuticals | $11.81
+2.8% | 7/7/2025 | | Boost Price Target | $18.00 ➝ $20.00 | Outperform | 00.00% | View details for Leerink Partners rating of KalVista Pharmaceuticals (NASDAQ:KALV) on 7/7/2025 |
RYTM Rhythm Pharmaceuticals | $100.21
0.0% | 7/7/2025 | | Initiated Coverage | $88.00 | Outperform | 00.00% | View details for Leerink Partners rating of Rhythm Pharmaceuticals (NASDAQ:RYTM) on 7/7/2025 |
ZLAB Zai Lab | $32.70
-2.9% | 6/30/2025 | | Set Price Target | $73.00 ➝ $75.00 | Outperform | 00.00% | View details for Leerink Partners rating of Zai Lab (NASDAQ:ZLAB) on 6/30/2025 |
NUVL Nuvalent | $88.00
+3.7% | 6/24/2025 | | Boost Price Target | $125.00 ➝ $140.00 | Outperform | 00.00% | View details for Leerink Partners rating of Nuvalent (NASDAQ:NUVL) on 6/24/2025 |
ABT Abbott Laboratories | $133.24
-0.8% | 6/16/2025 | | Initiated Coverage | $143.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Abbott Laboratories (NYSE:ABT) on 6/16/2025 |
BSX Boston Scientific | $97.28
+0.5% | 6/16/2025 | | Initiated Coverage | $118.00 | Outperform | 00.00% | View details for Leerink Partners rating of Boston Scientific (NYSE:BSX) on 6/16/2025 |
MDT Medtronic | $96.42
-1.5% | 6/16/2025 | | Initiated Coverage | $110.00 | Outperform | 00.00% | View details for Leerink Partners rating of Medtronic (NYSE:MDT) on 6/16/2025 |
IDXX IDEXX Laboratories | $628.75
-0.2% | 6/11/2025 | | Boost Price Target | $515.00 ➝ $580.00 | Outperform | 00.00% | View details for Leerink Partners rating of IDEXX Laboratories (NASDAQ:IDXX) on 6/11/2025 |
SMMT Summit Therapeutics | $22.65
-3.0% | 6/11/2025 | | Initiated Coverage | $12.00 | Underperform | 00.00% | View details for Leerink Partners rating of Summit Therapeutics (NASDAQ:SMMT) on 6/11/2025 |
INSM Insmed | $164.40
+1.6% | 6/10/2025 | | Boost Price Target | $100.00 ➝ $115.00 | Outperform | 00.00% | View details for Leerink Partners rating of Insmed (NASDAQ:INSM) on 6/10/2025 |
BNTX BioNTech | $104.48
-1.7% | 6/2/2025 | | Set Price Target | $112.00 | | 00.00% | View details for Leerink Partners rating of BioNTech (NASDAQ:BNTX) on 6/2/2025 |
ARVN Arvinas | $9.59
-1.6% | 6/2/2025 | | Reiterated Rating | $10.00 ➝ $9.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Arvinas (NASDAQ:ARVN) on 6/2/2025 |
A Agilent Technologies | $140.13
-0.5% | 5/30/2025 | | Boost Price Target | $135.00 | Buy | 00.00% | View details for Leerink Partners rating of Agilent Technologies (NYSE:A) on 5/30/2025 |
RCKT Rocket Pharmaceuticals | $3.67
+8.3% | 5/28/2025 | | Reiterated Rating | $37.00 ➝ $8.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 5/28/2025 |
FULC Fulcrum Therapeutics | $9.62
-0.1% | 5/23/2025 | | Upgrade | $4.00 ➝ $12.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Fulcrum Therapeutics (NASDAQ:FULC) on 5/23/2025 |
HALO Halozyme Therapeutics | $65.11
-0.1% | 5/13/2025 | | Downgrade | $47.00 | Market Perform ➝ Underperform | 00.00% | View details for Leerink Partners rating of Halozyme Therapeutics (NASDAQ:HALO) on 5/13/2025 |
JNJ Johnson & Johnson | $190.97
+0.7% | 5/13/2025 | | Downgrade | $169.00 ➝ $153.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Johnson & Johnson (NYSE:JNJ) on 5/13/2025 |
AMLX Amylyx Pharmaceuticals | $14.47
+7.3% | 5/7/2025 | | Upgrade | $4.00 ➝ $10.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Amylyx Pharmaceuticals (NASDAQ:AMLX) on 5/7/2025 |
VRTX Vertex Pharmaceuticals | $414.86
-1.5% | 5/6/2025 | | Reiterated Rating | $550.00 ➝ $503.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Vertex Pharmaceuticals (NASDAQ:VRTX) on 5/6/2025 |
NEO NeoGenomics | $8.97
-2.2% | 4/30/2025 | | Downgrade | $25.00 ➝ $9.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of NeoGenomics (NASDAQ:NEO) on 4/30/2025 |
PFE Pfizer | $25.22
-1.8% | 4/30/2025 | | Lower Price Target | $28.00 ➝ $26.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Pfizer (NYSE:PFE) on 4/30/2025 |
QTRX Quanterix | $5.99
-0.2% | 4/30/2025 | | Reiterated Rating | $12.00 ➝ $8.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Quanterix (NASDAQ:QTRX) on 4/30/2025 |
AKBA Akebia Therapeutics | $2.89
+1.4% | 4/28/2025 | | Initiated Coverage | $7.00 | Outperform | 00.00% | View details for Leerink Partners rating of Akebia Therapeutics (NASDAQ:AKBA) on 4/28/2025 |
DHR Danaher | $204.31
-0.3% | 4/23/2025 | | Boost Price Target | $225.00 ➝ $230.00 | Outperform | 00.00% | View details for Leerink Partners rating of Danaher (NYSE:DHR) on 4/23/2025 |
DHR Danaher | $204.31
-0.3% | 4/17/2025 | | Lower Price Target | $260.00 ➝ $225.00 | Outperform | 00.00% | View details for Leerink Partners rating of Danaher (NYSE:DHR) on 4/17/2025 |
IRWD Ironwood Pharmaceuticals | $1.77
+12.0% | 4/14/2025 | | Lower Price Target | $3.00 ➝ $1.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Ironwood Pharmaceuticals (NASDAQ:IRWD) on 4/14/2025 |
SYRE Spyre Therapeutics | $21.17
+19.7% | 4/8/2025 | | Initiated Coverage | $45.00 | Outperform | 00.00% | View details for Leerink Partners rating of Spyre Therapeutics (NASDAQ:SYRE) on 4/8/2025 |
CMPX Compass Therapeutics | $4.07
+4.4% | 4/2/2025 | | Upgrade | $4.00 ➝ $6.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Compass Therapeutics (NASDAQ:CMPX) on 4/2/2025 |
AIRS AirSculpt Technologies | $8.60
+0.6% | 3/31/2025 | | Lower Price Target | $6.50 ➝ $2.50 | Market Perform | 00.00% | View details for Leerink Partners rating of AirSculpt Technologies (NASDAQ:AIRS) on 3/31/2025 |
EQ Equillium | $1.44
-2.0% | 3/28/2025 | | Reiterated Rating | $3.00 ➝ $1.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Equillium (NASDAQ:EQ) on 3/28/2025 |
OPT Opthea | $3.41
+7.2% | 3/25/2025 | | Downgrade | $12.00 ➝ $1.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Opthea (NASDAQ:OPT) on 3/25/2025 |
LXEO Lexeo Therapeutics | $8.20
+2.1% | 3/24/2025 | | Lower Price Target | $19.00 ➝ $18.00 | Outperform | 00.00% | View details for Leerink Partners rating of Lexeo Therapeutics (NASDAQ:LXEO) on 3/24/2025 |
MEDP Medpace | $518.69
-2.3% | 3/24/2025 | | Initiated Coverage | $330.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Medpace (NASDAQ:MEDP) on 3/24/2025 |
RGNX REGENXBIO | $12.17
-0.4% | 3/18/2025 | | Set Price Target | $24.00 | | 00.00% | View details for Leerink Partners rating of REGENXBIO (NASDAQ:RGNX) on 3/18/2025 |
NRIX Nurix Therapeutics | $10.86
+8.8% | 3/17/2025 | | Initiated Coverage | $16.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Nurix Therapeutics (NASDAQ:NRIX) on 3/17/2025 |
STTK Shattuck Labs | $2.20
-7.9% | 3/17/2025 | | Initiated Coverage | $4.00 | Outperform | 00.00% | View details for Leerink Partners rating of Shattuck Labs (NASDAQ:STTK) on 3/17/2025 |
TENX Tenax Therapeutics | $7.77
-0.8% | 3/10/2025 | | Set Price Target | $20.00 | | 00.00% | View details for Leerink Partners rating of Tenax Therapeutics (NASDAQ:TENX) on 3/10/2025 |
CRMD CorMedix | $11.00
-2.4% | 3/7/2025 | | Initiated Coverage | $18.00 | Outperform | 00.00% | View details for Leerink Partners rating of CorMedix (NASDAQ:CRMD) on 3/7/2025 |
|
XERS Xeris Biopharma | $8.19
-0.1% | 3/7/2025 | | Boost Price Target | $5.00 ➝ $6.00 | Outperform | 00.00% | View details for Leerink Partners rating of Xeris Biopharma (NASDAQ:XERS) on 3/7/2025 |
LXRX Lexicon Pharmaceuticals | $1.64
+14.7% | 3/4/2025 | | Reiterated Rating | $2.00 ➝ $1.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Lexicon Pharmaceuticals (NASDAQ:LXRX) on 3/4/2025 |
PLRX Pliant Therapeutics | $1.54
+0.7% | 3/3/2025 | | Downgrade | $33.00 ➝ $2.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Pliant Therapeutics (NASDAQ:PLRX) on 3/3/2025 |
RXRX Recursion Pharmaceuticals | $5.91
-3.0% | 2/28/2025 | | Lower Price Target | $7.00 ➝ $6.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Recursion Pharmaceuticals (NASDAQ:RXRX) on 2/28/2025 |
HIMS Hims & Hers Health | $58.13
-0.1% | 2/25/2025 | | Boost Price Target | $24.00 ➝ $40.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Hims & Hers Health (NYSE:HIMS) on 2/25/2025 |
MAZE Maze Therapeutics | $28.76
+0.6% | 2/25/2025 | | Initiated Coverage | $28.00 | Outperform | 00.00% | View details for Leerink Partners rating of Maze Therapeutics (NASDAQ:MAZE) on 2/25/2025 |
BBNX Beta Bionics | $22.23
+0.5% | 2/24/2025 | | Initiated Coverage | $28.00 | Outperform | 00.00% | View details for Leerink Partners rating of Beta Bionics (NASDAQ:BBNX) on 2/24/2025 |
ATYR aTyr Pharma | $0.95
-4.7% | 2/18/2025 | | Initiated Coverage | $16.00 | Outperform | 00.00% | View details for Leerink Partners rating of aTyr Pharma (NASDAQ:ATYR) on 2/18/2025 |
MGM MGM Resorts International | $32.47
+0.5% | 2/13/2025 | | Downgrade | | Market Perform | 00.00% | View details for Leerink Partners rating of MGM Resorts International (NYSE:MGM) on 2/13/2025 |
CVS CVS Health | $76.78
-0.2% | 2/13/2025 | | Upgrade | $55.00 ➝ $75.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of CVS Health (NYSE:CVS) on 2/13/2025 |
GMAB Genmab A/S | $31.85
-2.7% | 2/13/2025 | | Upgrade | $27.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Genmab A/S (NASDAQ:GMAB) on 2/13/2025 |
TXG 10x Genomics | $11.71
-3.0% | 2/13/2025 | | Downgrade | $25.00 ➝ $12.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of 10x Genomics (NASDAQ:TXG) on 2/13/2025 |
CVS CVS Health | $76.78
-0.2% | 2/11/2025 | | Boost Price Target | $51.00 ➝ $55.00 | Market Perform | 00.00% | View details for Leerink Partners rating of CVS Health (NYSE:CVS) on 2/11/2025 |
AXSM Axsome Therapeutics | $122.52
+3.2% | 2/10/2025 | | Boost Price Target | $110.00 ➝ $150.00 | Outperform | 00.00% | View details for Leerink Partners rating of Axsome Therapeutics (NASDAQ:AXSM) on 2/10/2025 |
DOCS Doximity | $72.50
-1.4% | 2/7/2025 | | Upgrade | $60.00 ➝ $90.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Doximity (NASDAQ:DOCS) on 2/7/2025 |
HOLX Hologic | $68.62
+0.4% | 2/6/2025 | | Downgrade | $80.00 ➝ $75.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Hologic (NASDAQ:HOLX) on 2/6/2025 |
REGN Regeneron Pharmaceuticals | $569.90
+1.1% | 2/5/2025 | | Upgrade | $762.00 ➝ $834.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Regeneron Pharmaceuticals (NASDAQ:REGN) on 2/5/2025 |
REGN Regeneron Pharmaceuticals | $569.90
+1.1% | 2/4/2025 | | Lower Price Target | $980.00 ➝ $862.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Regeneron Pharmaceuticals (NASDAQ:REGN) on 2/4/2025 |
ISRG Intuitive Surgical | $443.76
-1.0% | 1/27/2025 | | Boost Price Target | $490.00 ➝ $548.00 | | 00.00% | View details for Leerink Partners rating of Intuitive Surgical (NASDAQ:ISRG) on 1/27/2025 |
JNJ Johnson & Johnson | $190.97
+0.7% | 1/23/2025 | | Lower Price Target | $182.00 ➝ $169.00 | Outperform | 00.00% | View details for Leerink Partners rating of Johnson & Johnson (NYSE:JNJ) on 1/23/2025 |
LLY Eli Lilly and Company | $854.40
+1.0% | 1/17/2025 | | Set Price Target | $950.00 | | 00.00% | View details for Leerink Partners rating of Eli Lilly and Company (NYSE:LLY) on 1/17/2025 |
MRNA Moderna | $27.53
-1.4% | 1/16/2025 | | Lower Price Target | $31.00 ➝ $27.00 | Underweight | 00.00% | View details for Leerink Partners rating of Moderna (NASDAQ:MRNA) on 1/16/2025 |
FDMT 4D Molecular Therapeutics | $9.56
-1.0% | 1/13/2025 | | Lower Price Target | $31.00 ➝ $27.00 | Outperform | 00.00% | View details for Leerink Partners rating of 4D Molecular Therapeutics (NASDAQ:FDMT) on 1/13/2025 |
MRK Merck & Co., Inc. | $87.38
+1.1% | 1/13/2025 | | Lower Price Target | $136.00 ➝ $119.00 | Outperform | 00.00% | View details for Leerink Partners rating of Merck & Co., Inc. (NYSE:MRK) on 1/13/2025 |
SPRY ARS Pharmaceuticals | $11.58
+4.2% | 1/13/2025 | | Boost Price Target | $26.00 ➝ $27.00 | Outperform | 00.00% | View details for Leerink Partners rating of ARS Pharmaceuticals (NASDAQ:SPRY) on 1/13/2025 |
VIR Vir Biotechnology | $6.04
-0.2% | 1/13/2025 | | Boost Price Target | $18.00 ➝ $20.00 | Outperform | 00.00% | View details for Leerink Partners rating of Vir Biotechnology (NASDAQ:VIR) on 1/13/2025 |
ALGN Align Technology | $131.87
-0.9% | 1/6/2025 | | Upgrade | $235.00 ➝ $280.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Align Technology (NASDAQ:ALGN) on 1/6/2025 |
DGX Quest Diagnostics | $181.35
+0.3% | 1/6/2025 | | Upgrade | $169.00 ➝ $174.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Quest Diagnostics (NYSE:DGX) on 1/6/2025 |
KYMR Kymera Therapeutics | $57.02
+1.3% | 12/27/2024 | | Reiterated Rating | $60.00 ➝ $60.00 | Outperform | 00.00% | View details for Leerink Partners rating of Kymera Therapeutics (NASDAQ:KYMR) on 12/27/2024 |
LVTX LAVA Therapeutics | $1.56
-1.3% | 12/12/2024 | | Reiterated Rating | $11.00 ➝ $2.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of LAVA Therapeutics (NASDAQ:LVTX) on 12/12/2024 |
ANIP ANI Pharmaceuticals | $90.78
-0.9% | 12/11/2024 | | Initiated Coverage | $80.00 | Outperform | 00.00% | View details for Leerink Partners rating of ANI Pharmaceuticals (NASDAQ:ANIP) on 12/11/2024 |
QTTB Q32 Bio | $3.24
+8.4% | 12/11/2024 | | Reiterated Rating | $68.00 ➝ $9.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Q32 Bio (NASDAQ:QTTB) on 12/11/2024 |
QURE uniQure | $63.65
+6.1% | 12/11/2024 | | Boost Price Target | $26.00 ➝ $44.00 | Outperform | 00.00% | View details for Leerink Partners rating of uniQure (NASDAQ:QURE) on 12/11/2024 |
MYGN Myriad Genetics | $7.74
+1.3% | 12/9/2024 | | Downgrade | $30.00 ➝ $21.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Myriad Genetics (NASDAQ:MYGN) on 12/9/2024 |
OKUR OnKure Therapeutics | $3.13
+3.0% | 12/5/2024 | | Initiated Coverage | $33.00 | Outperform | 00.00% | View details for Leerink Partners rating of OnKure Therapeutics (NASDAQ:OKUR) on 12/5/2024 |
RLAY Relay Therapeutics | $6.78
+11.0% | 12/4/2024 | | Lower Price Target | $19.00 ➝ $18.00 | Outperform | 00.00% | View details for Leerink Partners rating of Relay Therapeutics (NASDAQ:RLAY) on 12/4/2024 |
RLMD Relmada Therapeutics | $2.20
+3.3% | 12/4/2024 | | Reiterated Rating | $10.00 ➝ $1.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Relmada Therapeutics (NASDAQ:RLMD) on 12/4/2024 |
JANX Janux Therapeutics | $25.85
+6.8% | 12/3/2024 | | Boost Price Target | $79.00 ➝ $91.00 | Outperform | 00.00% | View details for Leerink Partners rating of Janux Therapeutics (NASDAQ:JANX) on 12/3/2024 |
CLYM Climb Bio | $1.89
+5.0% | 12/2/2024 | | Initiated Coverage | $10.00 | Outperform | 00.00% | View details for Leerink Partners rating of Climb Bio (NASDAQ:CLYM) on 12/2/2024 |
ELAN Elanco Animal Health | $20.06
-1.4% | 12/2/2024 | | Initiated Coverage | $14.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Elanco Animal Health (NYSE:ELAN) on 12/2/2024 |
IDXX IDEXX Laboratories | $628.75
-0.2% | 12/2/2024 | | Initiated Coverage | $500.00 | Outperform | 00.00% | View details for Leerink Partners rating of IDEXX Laboratories (NASDAQ:IDXX) on 12/2/2024 |
ZTS Zoetis | $143.32
-0.1% | 12/2/2024 | | Initiated Coverage | $215.00 | Outperform | 00.00% | View details for Leerink Partners rating of Zoetis (NYSE:ZTS) on 12/2/2024 |
AMGN Amgen | $295.43
+0.3% | 11/27/2024 | | Lower Price Target | $349.00 ➝ $302.00 | | 00.00% | View details for Leerink Partners rating of Amgen (NASDAQ:AMGN) on 11/27/2024 |
ABBV AbbVie | $231.03
-0.1% | 11/22/2024 | | Upgrade | $206.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of AbbVie (NYSE:ABBV) on 11/22/2024 |
JANX Janux Therapeutics | $25.85
+6.8% | 11/22/2024 | | Initiated Coverage | $79.00 | Outperform | 00.00% | View details for Leerink Partners rating of Janux Therapeutics (NASDAQ:JANX) on 11/22/2024 |
ACRS Aclaris Therapeutics | $1.95
+2.6% | 11/19/2024 | | Upgrade | $2.00 ➝ $7.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Aclaris Therapeutics (NASDAQ:ACRS) on 11/19/2024 |
EHAB Enhabit | $8.00
-2.6% | 11/19/2024 | | Reiterated Rating | $8.50 ➝ $8.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Enhabit (NYSE:EHAB) on 11/19/2024 |
ICLR Icon | $187.71
+0.7% | 11/19/2024 | | Reiterated Rating | $270.00 ➝ $255.00 | Outperform | 00.00% | View details for Leerink Partners rating of Icon (NASDAQ:ICLR) on 11/19/2024 |
IQV IQVIA | $203.16
+1.3% | 11/19/2024 | | Reiterated Rating | $260.00 ➝ $248.00 | Outperform | 00.00% | View details for Leerink Partners rating of IQVIA (NYSE:IQV) on 11/19/2024 |
RCKT Rocket Pharmaceuticals | $3.67
+8.3% | 11/19/2024 | | Lower Price Target | $46.00 ➝ $44.00 | Outperform | 00.00% | View details for Leerink Partners rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 11/19/2024 |
|
CMPX Compass Therapeutics | $4.07
+4.4% | 11/15/2024 | | Downgrade | $5.00 ➝ $4.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Compass Therapeutics (NASDAQ:CMPX) on 11/15/2024 |
LXEO Lexeo Therapeutics | $8.20
+2.1% | 11/13/2024 | | Lower Price Target | $20.00 ➝ $19.00 | Outperform | 00.00% | View details for Leerink Partners rating of Lexeo Therapeutics (NASDAQ:LXEO) on 11/13/2024 |
MASS 908 Devices | $8.80
-3.8% | 11/13/2024 | | Reiterated Rating | $12.00 ➝ $4.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of 908 Devices (NASDAQ:MASS) on 11/13/2024 |
ARDT Ardent Health | $14.33
-2.3% | 11/12/2024 | | Boost Price Target | $23.00 ➝ $25.00 | Outperform | 00.00% | View details for Leerink Partners rating of Ardent Health (NYSE:ARDT) on 11/12/2024 |
BMY Bristol Myers Squibb | $44.65
+0.2% | 11/12/2024 | | Upgrade | $55.00 ➝ $73.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Bristol Myers Squibb (NYSE:BMY) on 11/12/2024 |
NGNE Neurogene | $31.56
+22.2% | 11/12/2024 | | Boost Price Target | $45.00 ➝ $72.00 | Outperform | 00.00% | View details for Leerink Partners rating of Neurogene (NASDAQ:NGNE) on 11/12/2024 |
TECX Tectonic Therapeutic | $17.08
+11.2% | 11/11/2024 | | Boost Price Target | $49.00 ➝ $69.00 | Outperform | 00.00% | View details for Leerink Partners rating of Tectonic Therapeutic (NASDAQ:TECX) on 11/11/2024 |
XRAY DENTSPLY SIRONA | $12.22
-1.3% | 11/7/2024 | | Downgrade | | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of DENTSPLY SIRONA (NASDAQ:XRAY) on 11/7/2024 |
ZYME Zymeworks | $16.92
+1.4% | 11/7/2024 | | Upgrade | $10.00 ➝ $25.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Zymeworks (NYSE:ZYME) on 11/7/2024 |
BEAM Beam Therapeutics | $27.87
+3.2% | 11/6/2024 | | Upgrade | $27.00 ➝ $39.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Beam Therapeutics (NASDAQ:BEAM) on 11/6/2024 |
IDYA IDEAYA Biosciences | $26.79
-0.2% | 11/5/2024 | | Downgrade | $41.00 ➝ $27.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of IDEAYA Biosciences (NASDAQ:IDYA) on 11/5/2024 |
ZURA Zura Bio | $4.51
+3.9% | 11/4/2024 | | Initiated Coverage | $15.00 | Outperform | 00.00% | View details for Leerink Partners rating of Zura Bio (NASDAQ:ZURA) on 11/4/2024 |
NVST Envista | $20.19
-1.9% | 10/31/2024 | | Upgrade | $16.00 ➝ $23.00 | Underperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Envista (NYSE:NVST) on 10/31/2024 |
AQST Aquestive Therapeutics | $6.69
+7.9% | 10/25/2024 | | Boost Price Target | $12.00 ➝ $13.00 | Outperform | 00.00% | View details for Leerink Partners rating of Aquestive Therapeutics (NASDAQ:AQST) on 10/25/2024 |
DXCM DexCom | $68.08
+0.4% | 10/25/2024 | | Lower Price Target | $90.00 ➝ $87.00 | Outperform | 00.00% | View details for Leerink Partners rating of DexCom (NASDAQ:DXCM) on 10/25/2024 |
ICLR Icon | $187.71
+0.7% | 10/25/2024 | | Lower Price Target | $376.00 ➝ $270.00 | Outperform | 00.00% | View details for Leerink Partners rating of Icon (NASDAQ:ICLR) on 10/25/2024 |
TENX Tenax Therapeutics | $7.77
-0.8% | 10/24/2024 | | Initiated Coverage | $16.00 | Outperform | 00.00% | View details for Leerink Partners rating of Tenax Therapeutics (NASDAQ:TENX) on 10/24/2024 |
GILD Gilead Sciences | $116.74
-1.3% | 10/21/2024 | | Upgrade | $74.00 ➝ $96.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Gilead Sciences (NASDAQ:GILD) on 10/21/2024 |
LXRX Lexicon Pharmaceuticals | $1.64
+14.7% | 10/18/2024 | | Set Price Target | $6.00 | Outperform | 00.00% | View details for Leerink Partners rating of Lexicon Pharmaceuticals (NASDAQ:LXRX) on 10/18/2024 |
TNYA Tenaya Therapeutics | $2.02
+10.4% | 10/18/2024 | | Reiterated Rating | | Outperform | 00.00% | View details for Leerink Partners rating of Tenaya Therapeutics (NASDAQ:TNYA) on 10/18/2024 |
AMLX Amylyx Pharmaceuticals | $14.47
+7.3% | 10/18/2024 | | Set Price Target | $4.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Amylyx Pharmaceuticals (NASDAQ:AMLX) on 10/18/2024 |
BBIO BridgeBio Pharma | $54.79
-0.9% | 10/17/2024 | | Lower Price Target | $47.00 ➝ $46.00 | Outperform | 00.00% | View details for Leerink Partners rating of BridgeBio Pharma (NASDAQ:BBIO) on 10/17/2024 |
GH Guardant Health | $65.26
-0.1% | 10/17/2024 | | Lower Price Target | $60.00 ➝ $50.00 | Outperform | 00.00% | View details for Leerink Partners rating of Guardant Health (NASDAQ:GH) on 10/17/2024 |
ILMN Illumina | $96.45
-1.4% | 10/17/2024 | | Boost Price Target | $160.00 ➝ $200.00 | Outperform | 00.00% | View details for Leerink Partners rating of Illumina (NASDAQ:ILMN) on 10/17/2024 |
ISRG Intuitive Surgical | $443.76
-1.0% | 10/17/2024 | | Boost Price Target | $489.00 ➝ $502.00 | | 00.00% | View details for Leerink Partners rating of Intuitive Surgical (NASDAQ:ISRG) on 10/17/2024 |
MASS 908 Devices | $8.80
-3.8% | 10/17/2024 | | Lower Price Target | $15.00 ➝ $12.00 | Outperform | 00.00% | View details for Leerink Partners rating of 908 Devices (NASDAQ:MASS) on 10/17/2024 |
MIRM Mirum Pharmaceuticals | $73.82
+1.3% | 10/17/2024 | | Boost Price Target | $47.00 ➝ $49.00 | Outperform | 00.00% | View details for Leerink Partners rating of Mirum Pharmaceuticals (NASDAQ:MIRM) on 10/17/2024 |
NTRA Natera | $173.05
+0.6% | 10/17/2024 | | Boost Price Target | $140.00 ➝ $150.00 | Outperform | 00.00% | View details for Leerink Partners rating of Natera (NASDAQ:NTRA) on 10/17/2024 |
RVTY Revvity | $91.64
-0.1% | 10/17/2024 | | Boost Price Target | $130.00 ➝ $135.00 | Outperform | 00.00% | View details for Leerink Partners rating of Revvity (NYSE:RVTY) on 10/17/2024 |
TWST Twist Bioscience | $31.89
-2.7% | 10/17/2024 | | Boost Price Target | $45.00 ➝ $48.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Twist Bioscience (NASDAQ:TWST) on 10/17/2024 |
VCYT Veracyte | $34.93
-0.5% | 10/17/2024 | | Boost Price Target | $35.00 ➝ $40.00 | Outperform | 00.00% | View details for Leerink Partners rating of Veracyte (NASDAQ:VCYT) on 10/17/2024 |
VYGR Voyager Therapeutics | $5.15
-2.5% | 10/16/2024 | | Initiated Coverage | $15.00 | Outperform | 00.00% | View details for Leerink Partners rating of Voyager Therapeutics (NASDAQ:VYGR) on 10/16/2024 |
WVE WAVE Life Sciences | $8.19
+11.4% | 10/16/2024 | | Boost Price Target | $20.00 ➝ $22.00 | Outperform | 00.00% | View details for Leerink Partners rating of WAVE Life Sciences (NASDAQ:WVE) on 10/16/2024 |
MNMD Mind Medicine (MindMed) | $12.50
-2.4% | 10/14/2024 | | Initiated Coverage | $20.00 | Outperform | 00.00% | View details for Leerink Partners rating of Mind Medicine (MindMed) (NASDAQ:MNMD) on 10/14/2024 |
STOK Stoke Therapeutics | $29.90
-2.0% | 10/14/2024 | | Initiated Coverage | $18.00 | Outperform | 00.00% | View details for Leerink Partners rating of Stoke Therapeutics (NASDAQ:STOK) on 10/14/2024 |
HOLX Hologic | $68.62
+0.4% | 10/8/2024 | | Lower Price Target | $95.00 ➝ $90.00 | Outperform | 00.00% | View details for Leerink Partners rating of Hologic (NASDAQ:HOLX) on 10/8/2024 |
TVTX Travere Therapeutics | $26.07
-0.5% | 10/8/2024 | | Reiterated Rating | $20.00 ➝ $20.00 | Outperform | 00.00% | View details for Leerink Partners rating of Travere Therapeutics (NASDAQ:TVTX) on 10/8/2024 |
COR Cencora | $314.14
+1.1% | 10/7/2024 | | Lower Price Target | $277.00 ➝ $275.00 | Outperform | 00.00% | View details for Leerink Partners rating of Cencora (NYSE:COR) on 10/7/2024 |
MCK McKesson | $758.07
+0.3% | 10/7/2024 | | Lower Price Target | $665.00 ➝ $630.00 | Outperform | 00.00% | View details for Leerink Partners rating of McKesson (NYSE:MCK) on 10/7/2024 |
HUM Humana | $290.11
-2.7% | 10/2/2024 | | Downgrade | $400.00 ➝ $250.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Humana (NYSE:HUM) on 10/2/2024 |
AQST Aquestive Therapeutics | $6.69
+7.9% | 9/30/2024 | | Reiterated Rating | $10.00 ➝ $12.00 | Outperform | 00.00% | View details for Leerink Partners rating of Aquestive Therapeutics (NASDAQ:AQST) on 9/30/2024 |
AGIO Agios Pharmaceuticals | $42.43
-0.4% | 9/27/2024 | | Downgrade | $60.00 ➝ $56.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Agios Pharmaceuticals (NASDAQ:AGIO) on 9/27/2024 |
REGN Regeneron Pharmaceuticals | $569.90
+1.1% | 9/24/2024 | | Reiterated Rating | $1,175.00 ➝ $1,077.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Regeneron Pharmaceuticals (NASDAQ:REGN) on 9/24/2024 |
BHVN Biohaven | $17.23
+12.3% | 9/23/2024 | | Boost Price Target | $55.00 ➝ $60.00 | Outperform | 00.00% | View details for Leerink Partners rating of Biohaven (NYSE:BHVN) on 9/23/2024 |
SPRY ARS Pharmaceuticals | $11.58
+4.2% | 9/20/2024 | | Boost Price Target | $21.00 ➝ $25.00 | Outperform | 00.00% | View details for Leerink Partners rating of ARS Pharmaceuticals (NASDAQ:SPRY) on 9/20/2024 |
APLT Applied Therapeutics | $1.05
-1.9% | 9/19/2024 | | Boost Price Target | $11.00 ➝ $14.00 | Outperform | 00.00% | View details for Leerink Partners rating of Applied Therapeutics (NASDAQ:APLT) on 9/19/2024 |
FDMT 4D Molecular Therapeutics | $9.56
-1.0% | 9/19/2024 | | Reiterated Rating | $40.00 ➝ $36.00 | Outperform | 00.00% | View details for Leerink Partners rating of 4D Molecular Therapeutics (NASDAQ:FDMT) on 9/19/2024 |
PGNY Progyny | $20.57
0.0% | 9/19/2024 | | Lower Price Target | $25.00 ➝ $21.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Progyny (NASDAQ:PGNY) on 9/19/2024 |
ICLR Icon | $187.71
+0.7% | 9/18/2024 | | Initiated Coverage | $379.00 | Outperform | 00.00% | View details for Leerink Partners rating of Icon (NASDAQ:ICLR) on 9/18/2024 |
MRNA Moderna | $27.53
-1.4% | 9/17/2024 | | Lower Price Target | $60.00 ➝ $48.00 | Underperform | 00.00% | View details for Leerink Partners rating of Moderna (NASDAQ:MRNA) on 9/17/2024 |
|
ORKA Oruka Therapeutics | $25.55
+13.0% | 9/17/2024 | | Initiated Coverage | $44.00 | Outperform | 00.00% | View details for Leerink Partners rating of Oruka Therapeutics (NASDAQ:ORKA) on 9/17/2024 |
FULC Fulcrum Therapeutics | $9.62
-0.1% | 9/12/2024 | | Reiterated Rating | $4.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Fulcrum Therapeutics (NASDAQ:FULC) on 9/12/2024 |
INSP Inspire Medical Systems | $80.21
+2.1% | 9/10/2024 | | Boost Price Target | $167.00 ➝ $197.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Inspire Medical Systems (NYSE:INSP) on 9/10/2024 |
GERN Geron | $1.39
+0.7% | 9/9/2024 | | Initiated Coverage | $7.00 | Outperform | 00.00% | View details for Leerink Partners rating of Geron (NASDAQ:GERN) on 9/9/2024 |
IMUX Immunic | $0.92
+2.5% | 9/9/2024 | | Reiterated Rating | $5.00 | Outperform | 00.00% | View details for Leerink Partners rating of Immunic (NASDAQ:IMUX) on 9/9/2024 |
IRWD Ironwood Pharmaceuticals | $1.77
+12.0% | 9/9/2024 | | Initiated Coverage | $5.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Ironwood Pharmaceuticals (NASDAQ:IRWD) on 9/9/2024 |
KYMR Kymera Therapeutics | $57.02
+1.3% | 9/9/2024 | | Reiterated Rating | $60.00 | Outperform | 00.00% | View details for Leerink Partners rating of Kymera Therapeutics (NASDAQ:KYMR) on 9/9/2024 |
MNKD MannKind | $5.14
-5.5% | 9/9/2024 | | Initiated Coverage | $7.00 ➝ $8.00 | Outperform | 00.00% | View details for Leerink Partners rating of MannKind (NASDAQ:MNKD) on 9/9/2024 |
PLRX Pliant Therapeutics | $1.54
+0.7% | 9/9/2024 | | Initiated Coverage | $46.00 ➝ $33.00 | Outperform | 00.00% | View details for Leerink Partners rating of Pliant Therapeutics (NASDAQ:PLRX) on 9/9/2024 |
PRTC PureTech Health | $19.01
+3.6% | 9/9/2024 | | Initiated Coverage | $58.00 ➝ $45.00 | Outperform | 00.00% | View details for Leerink Partners rating of PureTech Health (NASDAQ:PRTC) on 9/9/2024 |
TRVI Trevi Therapeutics | $9.92
+1.0% | 9/9/2024 | | Initiated Coverage | $6.00 ➝ $7.00 | Outperform | 00.00% | View details for Leerink Partners rating of Trevi Therapeutics (NASDAQ:TRVI) on 9/9/2024 |
MCK McKesson | $758.07
+0.3% | 9/5/2024 | | Lower Price Target | $670.00 ➝ $665.00 | Outperform | 00.00% | View details for Leerink Partners rating of McKesson (NYSE:MCK) on 9/5/2024 |
PCVX Vaxcyte | $41.99
+3.1% | 9/3/2024 | | Boost Price Target | $106.00 ➝ $153.00 | Outperform | 00.00% | View details for Leerink Partners rating of Vaxcyte (NASDAQ:PCVX) on 9/3/2024 |
PEN Penumbra | $261.50
+1.0% | 9/3/2024 | | Initiated Coverage | $263.00 | Outperform | 00.00% | View details for Leerink Partners rating of Penumbra (NYSE:PEN) on 9/3/2024 |
RXRX Recursion Pharmaceuticals | $5.91
-3.0% | 9/3/2024 | | Lower Price Target | $9.00 ➝ $8.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Recursion Pharmaceuticals (NASDAQ:RXRX) on 9/3/2024 |
TXG 10x Genomics | $11.71
-3.0% | 9/3/2024 | | Initiated Coverage | $35.00 | Outperform | 00.00% | View details for Leerink Partners rating of 10x Genomics (NASDAQ:TXG) on 9/3/2024 |
ARCT Arcturus Therapeutics | $19.68
-7.2% | 8/12/2024 | | Initiated Coverage | $70.00 | Outperform | 00.00% | View details for Leerink Partners rating of Arcturus Therapeutics (NASDAQ:ARCT) on 8/12/2024 |
ARDT Ardent Health | $14.33
-2.3% | 8/12/2024 | | Initiated Coverage | $23.00 | Outperform | 00.00% | View details for Leerink Partners rating of Ardent Health (NYSE:ARDT) on 8/12/2024 |
SPRY ARS Pharmaceuticals | $11.58
+4.2% | 8/12/2024 | | Boost Price Target | $19.00 ➝ $20.00 | Outperform | 00.00% | View details for Leerink Partners rating of ARS Pharmaceuticals (NASDAQ:SPRY) on 8/12/2024 |
PGNY Progyny | $20.57
0.0% | 8/7/2024 | | Downgrade | $31.00 ➝ $25.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Progyny (NASDAQ:PGNY) on 8/7/2024 |
TBPH Theravance Biopharma | $14.51
+0.5% | 8/6/2024 | | Downgrade | $15.00 ➝ $10.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Theravance Biopharma (NASDAQ:TBPH) on 8/6/2024 |
WAT Waters | $330.48
+0.9% | 8/1/2024 | | Upgrade | $325.00 ➝ $375.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Waters (NYSE:WAT) on 8/1/2024 |
DHR Danaher | $204.31
-0.3% | 7/24/2024 | | Boost Price Target | $275.00 ➝ $280.00 | Outperform | 00.00% | View details for Leerink Partners rating of Danaher (NYSE:DHR) on 7/24/2024 |
HCA HCA Healthcare | $418.35
-1.9% | 7/24/2024 | | Boost Price Target | $367.00 ➝ $396.00 | Outperform | 00.00% | View details for Leerink Partners rating of HCA Healthcare (NYSE:HCA) on 7/24/2024 |
IONS Ionis Pharmaceuticals | $70.27
+0.4% | 7/24/2024 | | Upgrade | $53.00 ➝ $62.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 7/24/2024 |
TECX Tectonic Therapeutic | $17.08
+11.2% | 7/24/2024 | | Initiated Coverage | $49.00 | Outperform | 00.00% | View details for Leerink Partners rating of Tectonic Therapeutic (NASDAQ:TECX) on 7/24/2024 |
ALMS Alumis | $4.53
+2.3% | 7/23/2024 | | Initiated Coverage | $29.00 | Outperform | 00.00% | View details for Leerink Partners rating of Alumis (NASDAQ:ALMS) on 7/23/2024 |
BNTC Benitec Biopharma | $14.20
+0.7% | 7/22/2024 | | Initiated Coverage | $13.00 | Outperform | 00.00% | View details for Leerink Partners rating of Benitec Biopharma (NASDAQ:BNTC) on 7/22/2024 |
CELC Celcuity | $49.47
-0.1% | 7/22/2024 | | Initiated Coverage | $29.00 | Outperform | 00.00% | View details for Leerink Partners rating of Celcuity (NASDAQ:CELC) on 7/22/2024 |
LNTH Lantheus | $52.39
-2.2% | 7/11/2024 | | Boost Price Target | $106.00 ➝ $127.00 | Outperform | 00.00% | View details for Leerink Partners rating of Lantheus (NASDAQ:LNTH) on 7/11/2024 |
EHC Encompass Health | $123.06
-1.1% | 7/10/2024 | | Initiated Coverage | $100.00 | Outperform | 00.00% | View details for Leerink Partners rating of Encompass Health (NYSE:EHC) on 7/10/2024 |
HLVX HilleVax | $2.09
| 7/9/2024 | | Downgrade | $28.00 ➝ $2.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of HilleVax (NASDAQ:HLVX) on 7/9/2024 |
RVTY Revvity | $91.64
-0.1% | 7/8/2024 | | Initiated Coverage | $125.00 | Outperform | 00.00% | View details for Leerink Partners rating of Revvity (NYSE:RVTY) on 7/8/2024 |
SDGR Schrodinger | $20.65
-0.3% | 7/2/2024 | | Initiated Coverage | $29.00 | Outperform | 00.00% | View details for Leerink Partners rating of Schrodinger (NASDAQ:SDGR) on 7/2/2024 |
COR Cencora | $314.14
+1.1% | 6/27/2024 | | Reiterated Rating | $275.00 ➝ $275.00 | Outperform | 00.00% | View details for Leerink Partners rating of Cencora (NYSE:COR) on 6/27/2024 |
ALNY Alnylam Pharmaceuticals | $456.95
+1.4% | 6/25/2024 | | Boost Price Target | $138.00 ➝ $159.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 6/25/2024 |
SLDB Solid Biosciences | $6.40
+1.4% | 6/24/2024 | | Upgrade | $12.00 ➝ $12.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Solid Biosciences (NASDAQ:SLDB) on 6/24/2024 |
SRPT Sarepta Therapeutics | $23.13
-1.1% | 6/24/2024 | | Boost Price Target | $165.00 ➝ $230.00 | Outperform | 00.00% | View details for Leerink Partners rating of Sarepta Therapeutics (NASDAQ:SRPT) on 6/24/2024 |
MREO Mereo BioPharma Group | $2.10
+7.1% | 6/20/2024 | | Boost Price Target | $6.00 ➝ $8.00 | Outperform | 00.00% | View details for Leerink Partners rating of Mereo BioPharma Group (NASDAQ:MREO) on 6/20/2024 |
QTTB Q32 Bio | $3.24
+8.4% | 5/21/2024 | | Initiated Coverage | $54.00 | Outperform | 00.00% | View details for Leerink Partners rating of Q32 Bio (NASDAQ:QTTB) on 5/21/2024 |
BOLT Bolt Biotherapeutics | $5.90
-7.9% | 5/15/2024 | | Reiterated Rating | $60.00 ➝ $20.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Bolt Biotherapeutics (NASDAQ:BOLT) on 5/15/2024 |
AIRS AirSculpt Technologies | $8.60
+0.6% | 5/14/2024 | | Downgrade | $8.25 ➝ $5.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of AirSculpt Technologies (NASDAQ:AIRS) on 5/14/2024 |
EHAB Enhabit | $8.00
-2.6% | 5/14/2024 | | Upgrade | $8.50 | Underperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Enhabit (NYSE:EHAB) on 5/14/2024 |
AQST Aquestive Therapeutics | $6.69
+7.9% | 5/10/2024 | | Initiated Coverage | $8.00 | Outperform | 00.00% | View details for Leerink Partners rating of Aquestive Therapeutics (NASDAQ:AQST) on 5/10/2024 |
MYGN Myriad Genetics | $7.74
+1.3% | 5/8/2024 | | Upgrade | $25.00 ➝ $35.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Myriad Genetics (NASDAQ:MYGN) on 5/8/2024 |
CVS CVS Health | $76.78
-0.2% | 5/1/2024 | | Reiterated Rating | $87.00 ➝ $60.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of CVS Health (NYSE:CVS) on 5/1/2024 |
LXRX Lexicon Pharmaceuticals | $1.64
+14.7% | 4/30/2024 | | Initiated Coverage | $5.00 | Outperform | 00.00% | View details for Leerink Partners rating of Lexicon Pharmaceuticals (NASDAQ:LXRX) on 4/30/2024 |
IMCR Immunocore | $33.76
-0.7% | 4/29/2024 | | Initiated Coverage | $74.00 | Outperform | 00.00% | View details for Leerink Partners rating of Immunocore (NASDAQ:IMCR) on 4/29/2024 |
NGNE Neurogene | $31.56
+22.2% | 4/29/2024 | | Initiated Coverage | $46.00 | Outperform | 00.00% | View details for Leerink Partners rating of Neurogene (NASDAQ:NGNE) on 4/29/2024 |
XOMA XOMA Royalty | $38.77
+6.7% | 4/29/2024 | | Initiated Coverage | $40.00 | Outperform | 00.00% | View details for Leerink Partners rating of XOMA Royalty (NASDAQ:XOMA) on 4/29/2024 |
CVAC CureVac | $5.41
-0.2% | 4/25/2024 | | Downgrade | $12.00 ➝ $4.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of CureVac (NASDAQ:CVAC) on 4/25/2024 |
TNDM Tandem Diabetes Care | $14.82
-3.4% | 4/25/2024 | | Upgrade | $34.00 ➝ $45.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Tandem Diabetes Care (NASDAQ:TNDM) on 4/25/2024 |
RNAC Cartesian Therapeutics | $10.10
-1.3% | 4/23/2024 | | Initiated Coverage | $39.00 | Outperform | 00.00% | View details for Leerink Partners rating of Cartesian Therapeutics (NASDAQ:RNAC) on 4/23/2024 |
ANAB AnaptysBio | $31.77
-0.2% | 4/16/2024 | | Initiated Coverage | $47.00 | Outperform | 00.00% | View details for Leerink Partners rating of AnaptysBio (NASDAQ:ANAB) on 4/16/2024 |
LENZ LENZ Therapeutics | $46.25
-4.8% | 4/15/2024 | | Initiated Coverage | $32.00 | Outperform | 00.00% | View details for Leerink Partners rating of LENZ Therapeutics (NASDAQ:LENZ) on 4/15/2024 |
MNMD Mind Medicine (MindMed) | $12.50
-2.4% | 4/15/2024 | | Initiated Coverage | $20.00 | Outperform | 00.00% | View details for Leerink Partners rating of Mind Medicine (MindMed) (NASDAQ:MNMD) on 4/15/2024 |
ARDX Ardelyx | $5.06
| 4/5/2024 | | Initiated Coverage | $14.00 | Outperform | 00.00% | View details for Leerink Partners rating of Ardelyx (NASDAQ:ARDX) on 4/5/2024 |
LRMR Larimar Therapeutics | $4.55
-5.6% | 4/3/2024 | | Initiated Coverage | $25.00 | Outperform | 00.00% | View details for Leerink Partners rating of Larimar Therapeutics (NASDAQ:LRMR) on 4/3/2024 |
NUVL Nuvalent | $88.00
+3.7% | 4/1/2024 | | Upgrade | $69.00 ➝ $110.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Nuvalent (NASDAQ:NUVL) on 4/1/2024 |
SGMT Sagimet Biosciences | $8.62
+17.9% | 3/25/2024 | | Initiated Coverage | $26.00 | Outperform | 00.00% | View details for Leerink Partners rating of Sagimet Biosciences (NASDAQ:SGMT) on 3/25/2024 |
